Diffuse Large B-cell Lymphoma Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight's "Diffuse large B-cell lymphoma Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Diffuse Large B-Cell Lymphoma, historical and forecasted epidemiology as well as DLBCL Market Trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Diffuse Large B-cell Lymphoma Treatment Market Share @ Diffuse Large B-cell Lymphoma Market Outlook- https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Diffuse Large B-cell Lymphoma Pipeline Report
• In May 2025, Chia Tai Tianqing Pharmaceutical Group Co. Ltd. conducted a Phase Ib/II Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma.
• In May 2025, Merck Sharp & Dohme LLC announced a Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL).
• In May 2025, Suzhou Suncadia Biopharmaceuticals Co. Ltd. organized a phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.
• According to the DelveInsight estimates, the number of cases of males with DLBCL in 2023 was approximately 17,000 in the US.
• In the United States, the maximum number of DLBCL patients lies in the age group of 65-74 years, and the least number of patients lie in the age group of 0-19 years.
• Amongst EU4 and the UK, Germany accounted for the highest number of DLBCL cases, whereas Spain accounted for the lowest cases in 2023.
• As per the analysis, Stage IV accounts for the maximum number of DLBCL cases, that is nearly 12,000 cases, followed by Stage I in 2023 in the US.
• The leading Diffuse Large B-cell Lymphoma Companies such as AbbVie and Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, Debiopharm, Seagen, Takeda, AstraZeneca, Gilead Sciences and others.
• Promising Diffuse Large B-Cell Lymphoma Pipeline Therapies such as RITUXAN/MABTHERA (rituximab), YESCARTA (axicabtagene ciloleucel), KYMRIAH (tisagenlecleucel), XPOVIO (selinexor), POLIVY (polatuzumab vedotin-piiq), KEYTRUDA (pembrolizumab), COLUMVI (glofitamab), EPKINLY (epcoritamab), and others.

Stay ahead in the Diffuse Large B-cell Lymphoma Treatment Market with DelveInsight's Strategic Report @ Diffuse Large B-cell Lymphoma Treatment Market Size- https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diffuse Large B-cell Lymphoma Epidemiology Segmentation in the 7MM
• Total Diffuse Large B-cell Lymphoma incident cases
• Diffuse Large B-cell Lymphoma gender-specific cases
• Diffuse Large B-cell Lymphoma age-specific cases
• Diffuse Large B-cell Lymphoma type-specific cases
• Diffuse Large B-cell Lymphoma stage-specific Incidence Cases

Download the report to understand which factors are driving Diffuse Large B-cell Lymphoma Epidemiology trends @ Diffuse Large B-cell Lymphoma Prevalence- https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marketed Diffuse Large B-Cell Lymphoma Drugs
• EPKINLY (epcoritamab): Genmab and AbbVie
Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology. Epcoritamab is designed to bind to CD3 on T cells and CD20 on B cells and induce T-cell mediated killing of CD20+ cells. It was approved by the US FDA in May 2023, and by the EC in September 2023 for R/R DLBCL.

• YESCARTA (axicabtagene ciloleucel): Kite (Gilead Sciences)
YESCARTA (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T-cell immunotherapy. YESCARTA, a patient's T cells are harvested and genetically modified ex vivo by retroviral transduction to express a chimeric antigen receptor (CAR) comprising a murine anti-CD19 single-chain variable fragment (scFv) linked to CD28 and CD3-zeta costimulatory domains.

Emerging Diffuse Large B-Cell Lymphoma Drugs
• Enzastaurin (DB102): Denovo Biopharma
Enzastaurin (DB102) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K, and AKT pathways that have been studied in more than 3,000 patients across a range of solid and hematological tumor types. Eli Lilly originally developed DB102 and for which Denovo has acquired worldwide rights. Currently, the drug is in a Phase III trial evaluating the efficacy of DB102 in combination with R-CHOP vs. R-CHOP alone in newly diagnosed high-risk (IPI >=3) DLBCL patients with the biomarker DGM1 (Denovo Genomic Marker 1).

• Zilovertamab Vedotin: Merck
Zilovertamab vedotin is an antibody-drug conjugate comprising a humanized IgG1 monoclonal anti-ROR1, a proteolytically cleavable linker, and the antimicrotubule agent monomethyl auristatin E. The company is currently conducting a Phase II/III trial of Zilovertamab Vedotin in combination with standard of care options for the treatment of R/R DLBCL. Early Phase II results of zilovertamab vedotin of waveLINE-004 trial in patients diagnosed with R/R DLBCL who have either experienced disease progression after or were ineligible for ASCT and/or CAR-T therapy were presented at ASCO 2023, which showed the promising results.

To learn more about Diffuse Large B-cell Lymphoma Drugs guidelines, visit @ Diffuse Large B-cell Lymphoma Treatment Market Landscape- https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diffuse Large B-cell Lymphoma Companies
AbbVie and Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, Debiopharm, Seagen, Takeda, AstraZeneca, Gilead Sciences and others.

Diffuse Large B-Cell Lymphoma Drugs Market Insights
The landscape of Diffuse Large B-Cell Lymphoma drug development involves Protein kinase C (PKC) β inhibitor, BTK inhibitor, SYK inhibitor, CD30-directed antibody-drug conjugate, Immunotherapy and others. An antibody-drug conjugate (ADC) targets CD30, which is found on the surface of most classical Hodgkin lymphoma (HL) cells and in several types of non-Hodgkin lymphoma but not commonly found on healthy cells. Immunotherapy has become a standard treatment option for patients with various cancers. Promising immunotherapy approaches, such as chimeric antigen receptor (CAR) T cell therapy and therapeutic blockade of immune checkpoints, in particular cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 pathway (PD-1/PD-L1), have boosted the development of new therapeutic regimens for patients with cancer.

Diffuse large B-cell lymphoma Market Outlook
The Diffuse large B-cell lymphoma market growth over the forecast period is also being driven by an increase in pipeline candidates for the development of therapies for better recovery of DLBCL. Rituximab's approval altered the Diffuse Large B-cell Lymphoma treatment market landscape. For DLBCL patients, chemoimmunotherapy is the standard of care. In addition, numerous drugs that have recently been approved have transformed the treatment landscape for individuals with R/R DLBCL in 2L and 3L. The most common of the frontline regimens used today is called R-CHOP [rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone]. It is rituximab with a combination of chemotherapy drugs that are used usually every 3 weeks for a total of 6 cycles.

Learn more about the FDA-approved drugs for Diffuse Large B-cell Lymphoma @ Drugs for Diffuse Large B-cell Lymphoma Treatment- https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Diffuse Large B-cell Lymphoma Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Diffuse Large B-cell Lymphoma Companies- AbbVie and Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, Debiopharm, Seagen, Takeda, AstraZeneca, Gilead Sciences and others.
• Diffuse Large B-Cell Lymphoma Pipeline Therapies- RITUXAN/MABTHERA (rituximab), YESCARTA (axicabtagene ciloleucel), KYMRIAH (tisagenlecleucel), XPOVIO (selinexor), POLIVY (polatuzumab vedotin-piiq), KEYTRUDA (pembrolizumab), COLUMVI (glofitamab), EPKINLY (epcoritamab), and others.
• Diffuse Large B-cell Lymphoma Market Dynamics: Diffuse Large B-cell Lymphoma Market Drivers and Barriers
• Diffuse Large B-cell Lymphoma Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Diffuse Large B-cell Lymphoma Drugs in development @ Diffuse Large B-cell Lymphoma Clinical Trials Assessment - https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1 Key Insights
2 Report Introduction
3 Executive Summary
4 Key Events
5 Diffuse large B-cell lymphoma Epidemiology and Market Forecast Methodology
6 DLBCL Market Overview at a Glance in the 7MM
7 Disease Background and Overview
8 Treatment and Guidelines
9 Diffuse large B-cell lymphoma Epidemiology and Patient Population of 7MM
10. Diffuse large B-cell lymphoma Patient Journey
11 Marketed Drugs
12 Emerging Diffuse large B-cell lymphoma Drugs
13 DLBCL Market: 7MM Market Analysis
14. Diffuse large B-cell lymphoma Unmet Needs
15 SWOT Analysis
16 KOL Views
17 Diffuse Large B-cell Lymphoma Market Access and Reimbursement
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight

List of Top Selling Market Research Reports in 2025

CAR-T Pipeline- https://www.delveinsight.com/report-store/car-t-pipeline-insight
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Ly3454738 Drug Insight- https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight
NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Periodontal Disease Market- https://www.delveinsight.com/report-store/periodontal-disease-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
Urea Cycle Disorders Market- https://www.delveinsight.com/report-store/urea-cycle-disorders-pipeline-insight
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cardiac Implantable Electronic Devices Market- https://www.delveinsight.com/report-store/cardiac-implantable-electronic-devices-cieds-market
Positive Airway Pressure Device Market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/knee-reconstruction-devices-market
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Lice Infestations Market- https://www.delveinsight.com/report-store/lice-infestations-pipeline-insight
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market-insight
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.